These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35239088)

  • 41. The clinical value of controlled attenuation parameter for the noninvasive assessment of liver steatosis.
    Ferraioli G; Tinelli C; De Silvestri A; Lissandrin R; Above E; Dellafiore C; Poma G; Di Gregorio M; Maiocchi L; Maserati R; Filice C
    Liver Int; 2016 Dec; 36(12):1860-1866. PubMed ID: 27439331
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Value of controlled attenuation parameter in diagnosis of fatty liver using FibroScan].
    Xu L; Li P; Lu W; Shi Q; Shi R; Zhang X; Liu Y; Wang Q; Fan J; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):108-13. PubMed ID: 26983477
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Performance of B-mode ratio and 2D shear wave elastography for the detection and quantification of hepatic steatosis and fibrosis after liver transplantation.
    Dubois M; Ronot M; Houssel-Debry P; Brun V; Rayar M; Auger M; Beuzit L; Turlin B; Aubé C; Paisant A
    Eur J Gastroenterol Hepatol; 2020 Feb; 32(2):222-230. PubMed ID: 31464783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis.
    Wang Y; Fan Q; Wang T; Wen J; Wang H; Zhang T
    Int J Clin Exp Med; 2015; 8(10):17654-63. PubMed ID: 26770355
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.
    Runge JH; Smits LP; Verheij J; Depla A; Kuiken SD; Baak BC; Nederveen AJ; Beuers U; Stoker J
    Radiology; 2018 Feb; 286(2):547-556. PubMed ID: 28915103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees.
    Kim JK; Lee KS; Choi JR; Chung HJ; Jung DH; Lee KA; Lee JI
    Gut Liver; 2015 May; 9(3):405-10. PubMed ID: 25717046
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Role of Multiparametric US of the Liver for the Evaluation of Nonalcoholic Steatohepatitis.
    Sugimoto K; Moriyasu F; Oshiro H; Takeuchi H; Abe M; Yoshimasu Y; Kasai Y; Sakamaki K; Hara T; Itoi T
    Radiology; 2020 Sep; 296(3):532-540. PubMed ID: 32573385
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B.
    Mi YQ; Shi QY; Xu L; Shi RF; Liu YG; Li P; Shen F; Lu W; Fan JG
    Dig Dis Sci; 2015 Jan; 60(1):243-51. PubMed ID: 25194851
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values.
    Galaski J; Schulz L; Krause J; Lohse AW
    Z Gastroenterol; 2018 Jan; 56(1):36-42. PubMed ID: 29316576
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Accuracy of the ultrasound attenuation coefficient for the evaluation of hepatic steatosis: a systematic review and meta-analysis of prospective studies.
    Jang JK; Choi SH; Lee JS; Kim SY; Lee SS; Kim KW
    Ultrasonography; 2022 Jan; 41(1):83-92. PubMed ID: 34399043
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Relationship between liver controlled attenuation parameters and body fat mass and its distribution].
    Shao YL; Zhang SC; Wu JM; Guo FC; Liu LG; Ye CY; Yan T; Cao Q; Zhang F; Wang J; Mao YH; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2019 Oct; 27(10):754-759. PubMed ID: 31734988
    [No Abstract]   [Full Text] [Related]  

  • 52. Quantitative ultrasound, elastography, and machine learning for assessment of steatosis, inflammation, and fibrosis in chronic liver disease.
    Destrempes F; Gesnik M; Chayer B; Roy-Cardinal MH; Olivié D; Giard JM; Sebastiani G; Nguyen BN; Cloutier G; Tang A
    PLoS One; 2022; 17(1):e0262291. PubMed ID: 35085294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease.
    Zhu SH; Zheng KI; Hu DS; Gao F; Rios RS; Li G; Li YY; Byrne CD; Targher G; Chen YP; Zheng MH
    Eur J Gastroenterol Hepatol; 2021 Mar; 33(3):430-435. PubMed ID: 32398489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative ultrasound radiofrequency data analysis for the assessment of hepatic steatosis using the controlled attenuation parameter as a reference standard.
    Jeon SK; Joo I; Kim SY; Jang JK; Park J; Park HS; Lee ES; Lee JM
    Ultrasonography; 2021 Jan; 40(1):136-146. PubMed ID: 32654442
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of Radiologists and Deep Learning for US Grading of Hepatic Steatosis.
    Vianna P; Calce SI; Boustros P; Larocque-Rigney C; Patry-Beaudoin L; Luo YH; Aslan E; Marinos J; Alamri TM; Vu KN; Murphy-Lavallée J; Billiard JS; Montagnon E; Li H; Kadoury S; Nguyen BN; Gauthier S; Therien B; Rish I; Belilovsky E; Wolf G; Chassé M; Cloutier G; Tang A
    Radiology; 2023 Oct; 309(1):e230659. PubMed ID: 37787678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computer-aided B-mode ultrasound diagnosis of hepatic steatosis: a feasibility study.
    Thijssen JM; Starke A; Weijers G; Haudum A; Herzog K; Wohlsein P; Rehage J; De Korte CL
    IEEE Trans Ultrason Ferroelectr Freq Control; 2008; 55(6):1343-54. PubMed ID: 18599422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ultrasound-Based Attenuation Imaging for the Non-Invasive Quantification of Liver Fat - A Pilot Study on Feasibility and Inter-Observer Variability.
    Jesper D; Klett D; Schellhaas B; Pfeifer L; Leppkes M; Waldner M; Neurath MF; Strobel D
    IEEE J Transl Eng Health Med; 2020; 8():1800409. PubMed ID: 32617199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease.
    Piccinni R; Rodrigues SG; Montani M; Murgia G; Delgado MG; Casu S; Stirnimann G; Semmo N; De Gottardi A; Dufour JF; Berzigotti A
    Liver Int; 2020 May; 40(5):1151-1158. PubMed ID: 31823449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis?
    Chan WK; Nik Mustapha NR; Mahadeva S; Wong VW; Cheng JY; Wong GL
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1787-1794. PubMed ID: 29603365
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease].
    Hou MM; Yuan XW; Wang YQ; Zhang Y; Zhang SY; Yu SH; Nan YM
    Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):290-296. PubMed ID: 35462485
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.